A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo

Brenna Carey, Monica DeLay, Jane E. Strasser, Claudia Chalk, Kristen Dudley-McClain, Gregg N. Milligan, Hermine I. Brunner, Sherry Thornton, Raphael Hirsch

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.

Original languageEnglish (US)
Pages (from-to)65-76
Number of pages12
JournalClinical Immunology
Issue number1
StatePublished - Jul 2005


  • CTL
  • MHC
  • T lymphocytes
  • Tumor immunity
  • Vaccination
  • Viral immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo'. Together they form a unique fingerprint.

Cite this